Provided is a pharmaceutical composition for treating and/or preventing fatty liver disease, particularly nonalcoholic fatty liver disease, the pharmaceutical composition having an excellent ACC2-selective inhibitory action and having no side effects such as an increase in plasma triglyceride or a decrease in platelet concentration.
A pharmaceutical composition for treating and/or preventing fatty liver disease, the pharmaceutical composition comprising a compound represented by Formula (I):






wherein
R1 is haloalkyl or non-aromatic carbocyclyl,
R2 is a hydrogen atom or halogen,
R3 is halogen,
ring A is a group represented by the formula:










-L1- is —O—(CH2)—, —(CH2)2—, or the like,
R4 is alkyl or haloalkyl, and
R5 is alkylcarbonyl or carbamoyl,


or a pharmaceutically acceptable salt thereof.